Please login to the form below

Not currently logged in
Email:
Password:

Coreg CR study knocks a quarter off Flamelís shares

Shares in French drug delivery company Flamel Technologies fell by a quarter at the end of last week after a study of its daily controlled-release heart disease drug, Coreg CR, failed demonstrate augmented efficacy when compared with an existing twice-daily treatment, Coreg IR.

Shares in French drug delivery company Flamel Technologies fell by a quarter at the end of last week after a study of its daily controlled-release heart disease drug, Coreg CR, failed demonstrate augmented efficacy when compared with an existing twice-daily treatment, Coreg IR.

The results of the study were published in the Journal of Cardiac Failure.

As a result, Flamelís shares dropped a massive 24.6 per cent (USD 3.12) to settle at USD 9.56. The stock reached a 52-week low of USD 8.96 during the regular trading session.

Coreg IR is sold by GlaxoSmithKline (GSK) in the US, but it is currently experiencing generic competition from Israeli-headquartered Teva and US-based Mylan. Coreg CR was approved by the FDA in October 2006.

Merriman Curhan Ford analysts believe that formulary adoption of Coreg CR will be hindered in the near-term, limiting potential growth of prescriptions. They reaffirmed a "Neutral" rating to Flamel.

Flamel Technologies manufactures Coreg microparticles for GSK under a license agreement. Flamel's drug delivery technology is designed to control absorption of Coreg in the body.

28th August 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics